Ordering
Available Variants250 mg
CHA.89494-250mg
Price
€84.00
Available – Dispatch in 14 days
1 g
CHA.89494-1g
Price
€256.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
250 mg | CHA.89494-250mg | €84.00 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
1 g | CHA.89494-1g | €256.00 |
≥98% (TLC), powder, ATP-sensitive K⁺ channel activator
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C8H7ClN2O2S |
|---|---|
| CAS Number | 364-98-7 |
| Molecular Weight | 230.67 |
| NACRES | NA.77 |
| PubChem Substance ID | 24277831 |
| UNSPSC Code | 12352119 |
| EC Number | 206-668-1 |
| MDL number | MFCD00078578 |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302,H315,H319,H335 |
| pcodes | P261 - P264 - P270 - P301 + P312 - P302 + P352 - P305 + P351 + P338 |
| Hazard Classifications | Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3 |
| target_organs | Respiratory system |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | dust mask type N95 (US), Eyeshields, Gloves |
Technical Overview & Applications Use-case context
Diazoxide, with the chemical formula C8H7ClN2O2S and CAS number 364-98-7, is a potassium channel activator that has been utilized in the management of hypertension and hypoglycemia. It functions by opening potassium channels in smooth muscle cells, leading to vasodilation and a subsequent decrease in blood pressure. Additionally, diazoxide inhibits the release of insulin from pancreatic beta cells, thereby increasing blood glucose levels. This mechanism of action makes it an effective treatment for hypoglycemia, particularly in cases where insulin levels are elevated. Diazoxide has also been investigated for its potential role in protecting against cardiac ischemia-reperfusion injury, although its clinical use is primarily limited to the treatment of acute hypoglycemia and severe hypertension. Its administration is typically via intravenous injection, allowing for rapid onset of action.
